title: The Japanese Interferon Study Group (JISG) has established the efficacy of human interferon-beta for serious CMV pneumonitis in kidney recipients. Japanese Interferon Study Group.
abstract: The Japanese Interferon Study Group (JISG) is a research organization formed by 30 special hospitals for organ transplantation. A joint multi-centre, double-blind trial was conducted in order to investigate the efficacy of human interferon-beta (HuIFN-beta) against serious cytomegalovirus pneumonitis in kidney recipients.
authors: Secretariat of the JISG, Kidney Center, Tokyo Women's Medical College, Tokyo, Japan.
authors: K
authors: K
authors: Takahashi
authors: S
authors: S
authors: Teraoka
authors: K
authors: K
authors: Ota
authors: M
authors: M
authors: Kosaki
authors: H
authors: H
authors: Okazaki
mesh_terms: D000208:Acute Disease; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003371:Cough; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005334:Fever; D006084:Graft Rejection / Q000150:complications; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000209:etiology / Q000821:virology*; D011183:Postoperative Complications / Q000188:drug therapy / Q000821:virology; D011994:Recombinant Proteins; D015203:Reproducibility of Results
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins